Scaffold-Free 3D Atherosclerotic Plaque Model via Hanging Drop Culture
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current in vitro models of atherosclerotic plaques lack a human late-stage fibroatheroma model, which is crucial for understanding plaque development and regression, and existing models with scaffolds or matrices introduce biases and are not suitable for investigating drug effects on plaque disassembly or cell differentiation.
Innovation Solution
A bioengineered 3D model of human atherosclerotic plaques is generated using a method involving myeloid cells differentiated with protein kinase C agonists and fibroblasts in a hanging drop culture, creating a collagenous and lipid-rich matrix without external scaffolds, mimicking the human plaque environment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If scaffolds or matrices are used in in vitro plaque models, then structural support is provided, but biases are introduced that prevent investigation of drug effects on plaque disassembly and cell differentiation
Solution Approach 1:
The patent removes external scaffolds and matrices from the in vitro plaque model system. By extracting these artificial structural supports, the model allows endogenous matrix production by cells themselves, eliminating the bias that scaffolds introduce and enabling proper investigation of drug effects on plaque disassembly and cell differentiation.
Solution Approach 2:
The model enables cells to self-assemble the extracellular matrix without external scaffolds. Cells differentiate and produce their own collagenous and lipid-rich matrix, creating a more physiologically relevant structure that can be properly modulated by therapeutic interventions.
2Reliability
If existing in vitro models are used, then plaque formation can be studied, but they lack representation of human late-stage fibroatheroma
Solution Approach 1:
The patent creates a model with spatially differentiated cellular zones that mirror the heterogeneity of human fibroatheroma. Different cell types (macrophages, smooth muscle cells, fibroblasts, endothelial cells) are distributed in specific regions, with each zone having distinct functional properties that match the late-stage plaque architecture.
Solution Approach 2:
The model combines multiple cell types and extracellular matrix components to create a composite tissue structure that accurately represents human fibroatheroma. The integration of different cellular elements and their secreted products creates a heterogeneous microenvironment characteristic of late-stage plaques.
3Ease of manufacture
If animal models are used to study atherosclerosis, then plaque formation mechanisms can be investigated, but anatomical and physiological differences hamper translation to human pathophysiology
Solution Approach 1:
The patent creates an in vitro human-specific model that copies the key features of human atherosclerotic plaques without requiring animal subjects. By using human-derived cells and recapitulating human plaque architecture and composition in vitro, the model provides direct human relevance while avoiding the translational gaps between species.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This model provides a physiologically relevant, scaffold-free representation of human late-stage atherosclerotic plaques, allowing for the investigation of drug effects on plaque formation and regression without external scaffold influences, and can be used for drug screening and biomarker identification.
Implementation Method 1
myeloid cells differentiated with protein kinase C agonists
Implementation Method 2
hanging drop culture
Implementation Method 3
hanging drop culture
Implementation Method 4
creating a collagenous and lipid-rich matrix
Data Source
AI summary
The invention provides a method for the generation of a layered cellular 3 D microtissue aggregate, comprising the steps of contacting myeloid cells with a protein kinase C agonist, yielding primed myeloid cells; incubating the primed myeloid cells in the presence of LDL in a confined volume, particularly in a hanging drop culture; yielding a 3 D culture of myeloid cells; and incubating the 3 D culture together with fibroblasts in a hanging drop in the presence of LDL, yielding the layered cellular aggregate.